Merck & Co., Inc. (NYSE:MRK) is among the most profitable healthcare stocks to buy. On January 21, TheFly reported that BofA analysts included Merck & Co., Inc. in its “US 1 List,” which includes the firm’s top investment ideas.
A day earlier, Bernstein reiterated its Market Perform rating on Merck & Co., Inc., with an unchanged price target of $95. While discussing headwinds related to the company’s growth prospects within this year, the firm raised the question of whether meaningful growth beyond Keytruda may only emerge in 2027.
Billion Photos/Shutterstock.com
Additionally, Bernstein highlighted the company’s renewed focus on M&As, noting the company’s “willingness to spend tens of billions” on potential strategic deals. Despite this, the firm experiences “struggle to validate if there’s a path to build confidence” in Merck & Co., Inc.’s short-term growth momentum. Thus, their analysis indicates a performance in line with the general market.
Overall, Merck & Co., Inc. has mixed analyst sentiment, with slightly more than half of analysts recommending a Buy and the remaining 45% holding a cautious view. With a consensus 1-year median price target of $120, the stock boasts an upside potential of 10.93%.
Merck & Co., Inc. is a New Jersey-based healthcare company developing and manufacturing human health pharmaceuticals for a range of areas. Founded in 1891, the company is committed to saving and improving lives through the power of science.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
